Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Erluo, Chen"'
Autor:
Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo
Publikováno v:
Liver Cancer, Vol 10, Iss 3, Pp 275-284 (2021)
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). Results for the subgroup of patients from Asia are described.
Externí odkaz:
https://doaj.org/article/6811a292141f4067ae7851205840ec6a
Autor:
Kazuyoshi Ohkawa, Erluo Chen, Ho Yeong Lim, Yee Chao, Tatsuya Yamashita, Masayuki Kurosaki, Ann-Lii Cheng, Naoki Morimoto, Baek Yeol Ryoo, Abby B. Siegel, Kyung Hun Lee, Masatoshi Kudo, Sadahisa Ogasawara, Thomas Yau
Publikováno v:
Liver Cancer, Vol 10, Iss 3, Pp 275-284 (2021)
Liver Cancer
Liver Cancer
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). Results for the subgroup of patients from Asia are described.
Autor:
Baek-Yeol Ryoo, Ho Yeong Lim, Marcelo Garrido, Sadahisa Ogasawara, Yee Chao, Erluo Chen, Ann-Lii Cheng, Josephine M. Norquist, Thomas Yau, Bruno Daniele, Masatoshi Kudo, Valeriy Breder, Richard S. Finn, Stephen L. Chan, Philippe Merle, Julien Edeline, Andrew X. Zhu, Amit S. Kulkarni, Abby B. Siegel, Mohamed Bouattour
Publikováno v:
Cancer. 127:865-874
Background Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC)
Autor:
Chie-Schin Shih, Erluo Chen, Sukrut Shah, Ian Chau, Anneli Elme, Eric Van Cutsem, Josep Tabernero, Ferdinando De Vita, David Adelberg, Mustafa Ozguroglu, Joseph Chao, Harry H. Yoon, Chia Jui Yen, Zev A. Wainberg, Yung-Jue Bang, Charles S. Fuchs, Jeeyun Lee, Kohei Shitara, Gregory Landers, Kei Muro, Pooja Bhagia, Daniel V.T. Catenacci
Importance Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors. Objective To evaluate the antitumor activity of pembrolizumab therapy vs chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b133ec17bebab697e21df24abb6a18
http://hdl.handle.net/11591/461870
http://hdl.handle.net/11591/461870
Autor:
Harold Richardson, Christine Fleming, Josephine Palmer, Erluo Chen, Robert Lannigan, The Microbiology Committee
Publikováno v:
Canadian Journal of Infectious Diseases, Vol 7, Iss 4, Pp 237-242 (1996)
OBJECTIVE: Diagnostic parasitology services in Ontario were assessed to determine whether the reduction in the number of provider laboratories from 209 to 70 over the period 1977 to 1994 has affected the availability and quality of service.
Externí odkaz:
https://doaj.org/article/5f7a19711cc44511a60c38c62a2a34fe
Autor:
Marcelo Garrido, Valeriy Breder, Erluo Chen, Jennifer J. Knox, Scot Ebbinghaus, Thomas Yau, Bruno Daniele, Abby B. Siegel, Sadahisa Ogasawara, Yee Chao, Philippe Merle, Mohamed Bouattour, Julien Edeline, Ann-Lii Cheng, Ho Yeong Lim, Richard S. Finn, Masatoshi Kudo, Stephen L. Chan, Baek-Yeol Ryoo, Andrew X. Zhu
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(3)
PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this pop
Autor:
Ho Yeong Lim, Baek-Yeol Ryoo, Thomas Yau, Yee Chao, Masatoshi Kudo, Naoki Morimoto, Ann-Lii Cheng, Sadahisa Ogasawara, Erluo Chen, Abby B. Siegel, Kazuyoshi Ohkawa, Tatsuya Yamashita, Masayuki Kurosaki, Kyung-Hun Lee
Publikováno v:
Journal of Clinical Oncology. 38:526-526
526 Background: Pembro received accelerated approval for second-line therapy in aHCC based on KEYNOTE-224 (phase 2). KEYNOTE-240 (NCT02702401) is a randomized, phase 3 study of pembro v BSC in previously treated aHCC. We report outcomes for the Asian
Autor:
A-L Cheng, Marcelo Garrido, Amit S. Kulkarni, Masatoshi Kudo, Erluo Chen, Thomas Yau, Josephine M. Norquist, Richard S. Finn, Valeriy Breder, Sheng-Ju Chan, Yee Chao, Baek-Yeol Ryoo, Andrew X. Zhu, Sadahisa Ogasawara, H. Y. Lim, Bruno Daniele, Philippe Merle, Julien Edeline, Abby B. Siegel, Mohamed Bouattour
Publikováno v:
Annals of Oncology. 30:v256
Background KEYNOTE-240 (ClinicalTrials.gov: NCT02702401) is a double-blind, randomized, placebo-controlled, phase 3 trial that evaluated pembro 200 mg every 3 weeks compared with BSC in pts with advanced HCC who were previously systemically treated.
Autor:
Ronald Nahass, Oren Shibolet, I.N. Gendrano, Brian Conway, Anne F Luetkemeyer, Jason Grebely, Bach-Yen Nguyen, Erluo Chen, Alain H. Litwin, E.J. Gane, H.-C. Huang, Frederick L. Altice, Eliav Barr, Heather L. Platt, Michael N. Robertson, Janice Wahl, Gregory J. Dore, Olav Dalgard, Cheng Yuan Peng
BACKGROUND: The fixed-dose combination of EBR 50 mg, an NS5A inhibitor, and GZR 100 mg, an NS3/4 protease inhibitor (EBR/GZR), is a highly effective and well-tolerated all-oral, once-daily regimen in diverse populations of hepatitis C virus (HCV) gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb873ae8115cbbcf3c001dc306c706e0
https://europepmc.org/articles/PMC6508009/
https://europepmc.org/articles/PMC6508009/
Autor:
Scot Ebbinghaus, Marcelo Garrido, Abby B. Siegel, Jennifer J. Knox, Mohamed Bouattour, Andrew X. Zhu, Valeriy Breder, Richard S. Finn, Yee Chao, Sadahisa Ogasawara, H. Y. Lim, Stephen L. Chan, Baek-Yeol Ryoo, A-L Cheng, Terrence M. Yau, Erluo Chen, Philippe Merle, Julien Edeline, Bruno Daniele, Masatoshi Kudo
Publikováno v:
Publons